Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 9
Submit an article Journal homepage
1,142
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Olverembatinib for myeloid/lymphoid neoplasm associated with eosinophilia and FGFR1 rearrangement

Yiru Yana State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, P.R. China;b Tianjin Institutes of Health Science, Tianjin, P.R. ChinaView further author information
,
Shiqiang Qua State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, P.R. China;b Tianjin Institutes of Health Science, Tianjin, P.R. China;c MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, P.R. ChinaView further author information
,
Jinqin Liua State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, P.R. China;b Tianjin Institutes of Health Science, Tianjin, P.R. ChinaView further author information
,
Chengwen Lid Hematologic Pathology Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, P.R. ChinaView further author information
,
Xiao Yane Department of Hematology, The First Affiliated Hospital of Ningbo University, Ningbo Clinical Research Center for Hematologic Malignancies, Ningbo, P.R. ChinaView further author information
,
Zefeng Xua State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, P.R. China;b Tianjin Institutes of Health Science, Tianjin, P.R. China;c MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, P.R. ChinaView further author information
,
Tiejun Qinc MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, P.R. ChinaView further author information
,
Yujiao Jiad Hematologic Pathology Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, P.R. ChinaView further author information
,
Lijuan Panc MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, P.R. ChinaView further author information
,
Qingyan Gaoc MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, P.R. ChinaORCID Iconhttps://orcid.org/0000-0002-1168-2719View further author information
ORCID Icon,
Meng Jiaoc MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, P.R. ChinaView further author information
,
Bing Lia State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, P.R. China;b Tianjin Institutes of Health Science, Tianjin, P.R. China;c MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, P.R. ChinaView further author information
,
Robert Peter Galef Centre for Hematology, Department of Immunology and Inflammation, Imperial College of Science, Technology and Medicine, London, United KingdomView further author information
&
Zhijian Xiaoa State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, P.R. China;b Tianjin Institutes of Health Science, Tianjin, P.R. China;c MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, P.R. China;d Hematologic Pathology Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, P.R. ChinaCorrespondence[email protected]
View further author information
 show all
Pages 1605-1610 | Received 28 Nov 2023, Accepted 06 Mar 2023, Published online: 24 Jun 2023

References

  • Khoury JD, Solary E, Abla O, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022; 36(7):1703–1719. doi: 10.1038/s41375-022-01613-1.
  • Reiter A, Gotlib J. Myeloid neoplasms with eosinophilia. Blood. 2017;129(6):704–714. doi: 10.1182/blood-2016-10-695973.
  • Chen M, Wang K, Cai X, et al. Myeloid/lymphoid neoplasm with CEP110-FGFR1 fusion: an analysis of 16 cases show common features and poor prognosis. Hematology. 2021; 26(1):153–159. doi: 10.1080/16078454.2020.1854493.
  • Umino K, Fujiwara SI, Ikeda T, et al. Clinical outcomes of myeloid/lymphoid neoplasms with fibroblast growth factor receptor-1 (FGFR1) rearrangement. Hematology. 2018; 23(8):470–477. doi: 10.1080/10245332.2018.1446279.
  • Dhillon S. Olverembatinib: first approval. Drugs. 2022; 82(4):469–475. doi: 10.1007/s40265-022-01680-9.
  • Jiang Q, Li Z, Qin Y, et al. Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial. J Hematol Oncol. 2022; 15(1):113. doi: 10.1186/s13045-022-01334-z.
  • Wang Y, Zhang L, Tang X, et al. GZD824 as a FLT3, FGFR1 and PDGFRα inhibitor against leukemia in vitro and in vivo. Transl Oncol. 2020; 13(4):100766. doi: 10.1016/j.tranon.2020.100766.
  • Qu SQ, Wang Y, Sun XJ. [FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutant of PDGFRA gene: a case report and literature review]. Zhonghua Xue Ye Xue Za Zhi. 2013; 34(2):159–161.
  • Zhang Y, Qu S, Wang Q, et al. A novel fusion of PDGFRB to TSC1, an intrinsic suppressor of mTOR-signaling pathway, in a chronic eosinophilic leukemia patient with t(5;9)(q32;q34). Leuk Lymphoma. 2018; 59(10):2506–2508. doi: 10.1080/10428194.2018.1427855.
  • Alves R, Gonçalves AC, Rutella S, et al. Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia-from molecular mechanisms to clinical relevance. Cancers. 2021; 13(19):4820. doi: 10.3390/cancers13194820.
  • Ren X, Pan X, Zhang Z, et al. Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib. J Med Chem. 2013; 56(3):879–894. doi: 10.1021/jm301581y.
  • Jiang K, Tang X, Guo J, et al. GZD824 overcomes FGFR1-V561F/M mutant resistance in vitro and in vivo. Cancer Med. 2021; 10(14):4874–4884. doi: 10.1002/cam4.4041.
  • Lin Q, Chen X, Qu L, et al. Characterization of the cholangiocarcinoma drug pemigatinib against FGFR gatekeeper mutants. Commun Chem. 2022; 5(1):100. doi: 10.1038/s42004-022-00718-z.
  • Dreyling MH, Schrader K, Fonatsch C, et al. MLL and CALM are fused to AF10 in morphologically distinct subsets of acute leukemia with translocation t(10;11): both rearrangements are associated with a poor prognosis. Blood. 1998; 91(12):4662–4667.
  • Ren M, Qin H, Kitamura E, et al. Dysregulated signaling pathways in the development of CNTRL-FGFR1-induced myeloid and lymphoid malignancies associated with FGFR1 in human and mouse models. Blood. 2013; 122(6):1007–1016. doi: 10.1182/blood-2013-03-489823.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.